KPV is one of the smallest peptides in research circulation — a tripeptide of just three amino acids — yet it carries an unusual pedigree: it is the tail end of a much larger hormone. The sequence is Lysine–Proline–Valine (Lys-Pro-Val), and it corresponds to the final three residues of alpha-melanocyte-stimulating hormone (α-MSH). That origin is the whole reason KPV is studied at all, because the published literature reports that this short fragment keeps a particular property of the parent hormone while shedding another. This overview describes what KPV is at the molecular level, how it relates to α-MSH, and what the published research has actually measured in laboratory models.
What KPV is
KPV is a tripeptide — a chain of three amino acids joined by peptide bonds. Reading the sequence by single-letter code gives the name: K for lysine, P for proline, and V for valine, hence “KPV.” Written out, it is Lys-Pro-Val. Its molecular formula is C₁₆H₃₀N₄O₄, corresponding to a molecular weight of roughly 342.4 g/mol, and it is indexed under CAS number 67727-97-3.
By the standards of the peptides most often discussed in research settings, that is tiny. A compound such as a GHRH analog runs to twenty-nine or more residues; KPV is three. Its interest does not come from size or complexity but from where the sequence is found in nature: it is a fragment carved off the end of a well-characterized signaling hormone.
The connection to α-MSH
Alpha-melanocyte-stimulating hormone is a thirteen-amino-acid peptide hormone derived from the precursor protein proopiomelanocortin (POMC). It is best known for its role in pigmentation — it stimulates melanocytes, the cells that produce melanin — but it is also extensively described in the literature as a signaling molecule that acts on the melanocortin receptor family and has been characterized as an endogenous mediator with anti-inflammatory and immunomodulatory properties (Brzoska et al., Endocrine Reviews, 2008).
KPV is the C-terminal fragment of that hormone — specifically residues 11–13, the last three amino acids of the α-MSH sequence. In peptide nomenclature this segment is sometimes written as α-MSH(11–13). Because it sits at the very end of the parent molecule, KPV is structurally a self-contained “tail” that researchers can synthesize and study on its own, separate from the rest of the hormone.
The significance of that separation is the central theme of the KPV literature. Α-MSH has two broad faces — its pigmentary (melanocortin-receptor) activity and a distinct set of anti-inflammatory properties — and the two appear to map to different parts of the molecule.
Activity retained, activity dropped
The portion of α-MSH responsible for binding the melanocortin receptors — the pharmacophore that drives pigmentation — resides in the core of the hormone, not its C-terminus. KPV, being only the C-terminal three residues, lacks that binding motif. The published reviews describe this directly: KPV does not contain the sequence motif required for binding to the known melanocortin receptors, and so it does not carry the parent hormone’s pigmentary activity (Brzoska et al., Advances in Experimental Medicine and Biology, 2010).
What the literature reports is that, despite lacking that receptor-binding core, the tripeptide retains much of the anti-inflammatory activity associated with the full hormone in laboratory models. The 2010 review by Brzoska and colleagues frames KPV as a C-terminal fragment that lacks the entire sequence motif needed for melanocortin-receptor binding yet preserves a large share of the anti-inflammatory capacity measured for α-MSH (Brzoska et al., Advances in Experimental Medicine and Biology, 2010). In other words, the research describes the two activities as separable, with KPV representing the anti-inflammatory side decoupled from the pigmentary side.
This is what makes the fragment a recurring subject of study rather than a curiosity. It allowed researchers to ask whether the anti-inflammatory signaling of α-MSH could be examined in a minimal three-residue peptide that does not engage the pigment-producing receptor pathway.
What the published research measured
The mechanistic studies on KPV are framed almost entirely around inflammatory signaling pathways in cells and animal models. Two findings recur across the literature, and both are reported strictly as measurements made in research systems:
- NF-κB signaling. NF-κB is a transcription factor that switches on many inflammation-related genes. In cell-based work, KPV was reported to inhibit activation of the NF-κB pathway, and the same study reported reduced activation of MAP kinase inflammatory signaling, with these effects observed at nanomolar concentrations of the peptide (Dalmasso et al., Gastroenterology, 2008).
- Pro-inflammatory cytokines. The same body of work reported that KPV reduced the secretion of pro-inflammatory cytokines in the cell and animal models studied, and that oral administration was associated with reduced markers of chemically induced colitis in mice (Dalmasso et al., Gastroenterology, 2008).
That study also described a route of entry: it reported that KPV is taken up by PepT1, a di- and tripeptide transporter expressed in intestinal epithelial and immune cells, which the authors used to explain how a tripeptide could reach an intracellular target like NF-κB (Dalmasso et al., Gastroenterology, 2008).
Separately, a study in two murine models of inflammatory bowel disease — a chemically induced (DSS) colitis model and a T-cell transfer model — reported that KPV reduced colonic inflammation as assessed by histological scoring, weight change, and myeloperoxidase activity, a marker of immune-cell infiltration (Kannengiesser et al., Inflammatory Bowel Diseases, 2008). Notably, that study also tested KPV in mice with a non-functional melanocortin-1 receptor and still measured an anti-inflammatory effect, which the authors interpreted as evidence that the effect did not depend on that receptor — consistent with the structural picture of a fragment that lacks the melanocortin-binding core (Kannengiesser et al., Inflammatory Bowel Diseases, 2008).
Every one of these observations is a measurement made in cell cultures or animal models. They describe what the cited investigators recorded in their experimental systems; they are not statements about any effect in a person.
Where KPV appears in research blends
Because it is a single, well-defined tripeptide, KPV is also a component of multi-peptide research preparations. It is one of the peptides in the KLOW blend, a combination preparation that pairs KPV with several other commonly studied peptides. As a standalone compound it is catalogued as KPV. In either form the molecule is the same Lys-Pro-Val tripeptide described above — the C-terminal fragment of α-MSH.
Frequently asked questions
What is the KPV peptide?
KPV is a tripeptide made of the amino acids lysine, proline, and valine (Lys-Pro-Val). It corresponds to the C-terminal three residues — positions 11 to 13 — of the hormone alpha-melanocyte-stimulating hormone (α-MSH).
What does the name “KPV” mean?
The letters are the single-letter amino acid codes for the three residues in the sequence: K is lysine, P is proline, and V is valine. So “KPV” is simply shorthand for Lys-Pro-Val.
How is KPV related to alpha-MSH?
KPV is a fragment of α-MSH — specifically its last three amino acids (residues 11–13). Α-MSH is a thirteen-residue hormone, and KPV is the C-terminal tail of that sequence, studied on its own.
Does KPV cause pigmentation the way α-MSH does?
Published reviews report that KPV lacks the sequence motif required to bind the melanocortin receptors that drive pigmentation, so it does not carry the parent hormone’s pigmentary activity (Brzoska et al., 2010). It is studied for the anti-inflammatory signaling associated with α-MSH rather than its pigment-related activity.
What have studies measured about KPV’s mechanism?
In laboratory models, studies reported that KPV inhibited activation of the NF-κB and MAP kinase inflammatory signaling pathways and reduced pro-inflammatory cytokine secretion, with uptake mediated by the peptide transporter PepT1 (Dalmasso et al., 2008). These are measurements in cells and animal models, not effects in humans.
Is KPV part of the KLOW blend?
Yes. KPV is one of the peptides included in the KLOW blend, a multi-peptide research preparation. It is also catalogued as a standalone compound.
References
- Brzoska T, et al. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives for the treatment of immune-mediated inflammatory diseases. Endocrine Reviews. 2008. PMID: 18612139.
- Brzoska T, et al. Terminal signal: anti-inflammatory effects of alpha-melanocyte-stimulating hormone related peptides beyond the pharmacophore. Advances in Experimental Medicine and Biology. 2010. PMID: 21222263.
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008. PMID: 18061177.
- Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008. PMID: 18092346.
For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.
